Vital Signs at a Glance

Transcription

1 1

2 Vital Signs at a Glance Vital Signs is a leading designer, manufacturer, and marketer of airway management products for the anesthesia, respiratory/critical care, interventional cardiology/radiology, and sleep disorder markets Headquartered in Totowa, New Jersey Traded on Nasdaq since August 1990 Product sales in over 73 countries worldwide 25% of revenue derived internationally 1,257 total FTE employees worldwide Vital Signs headquarters 2

3 Forward Looking Information Except for historical information discussed, the statements made today are forward-looking statements that involve risks and uncertainties. Investors are cautioned that such statements are only predictions and that actual events or results may differ materially. These forward-looking statements speak only as of this date. We undertake no obligation to publicly release the results of any revisions to the forward-looking statements made today to reflect events or circumstances after today, or to reflect the occurrence of unanticipated events.

4 30+ Consecutive Years of Revenue Growth $225 $200 $175 $ Millions $150 $125 $100 CAGR: 18% $75 $50 $25 $0 '73 '74 '75 '76 '77 '78 '79 '80 '81 '82 '83 '84 '85 '86 '87 '88 '89 '90 '91 '92 '93 '94 '95 '96 '97 '98 '99 '00 '01 '02 '03 '04 '05 '06 '07 4

5 A Tradition of Innovation 1975: Clear (non-conductive) anesthesia breathing circuit 1980: Dry heparin Arterial Blood Gas sampler (patented) 1982: Flow independent PEEP valve (patented) 1983: Stat Blue manual resuscitator (patented) 1990: Super Circuit general anesthesia kit 1991: BabySafe infant resuscitation adjustable pressure relief valve (patented) 1992: Actar CPR training manikin (patented) 2001: Limb-O single tube, dual lumen breathing circuit (patented) 1997: Patient/Catheter isolation closed suction device (patented) 2003: PV 10i intelligent CPAP machine (patented) 2007: Vivo 30/40 and isleep (patented) : Jackson-Rees and Piggyback circuits 1985: Fiber optic laryngoscope blade (patented) 1988: Single patient use pentamidine nebulizer system 1996: Latex-free anesthesia breathing system 2000: Sure-Lok Needle protection device (patented) 2006: EBM latex free manufacturing (patented) 1981: Clear air-filled cushion face mask (prevents aspiration) 1987: Blood pressure cuff and pressure infusor 1999: ACCU-PEEP patented PEEP valve 2005: C-CO 2 Indicator (patented) 5

6 IP Portfolio Over 125 patents with a pipeline of patents pending in the application process Key patented products include Enflow, Limb-O, Latexfree Breathing Bag, Broselow Patents by Segment Anesthesia Respiratory Interventional Cardiology Sleep Emergency 6

7 Segment Overview - FY 2007 Anesthesia Respiratory/ Critical Care Sleep / Ventilation Revenue: $74.8 mm 36.4% Revenue: $46.3 mm 22.5% Revenue: $48.8 mm 23.8% Revenue: $28.6 mm 14.0 % #1 in Traditional Anesthesia Circuits (43% mkt share) 1 Including patented Limbo circuit (49.6% mkt share) #1 in Pressure infusors (60% mkt share) 1 1 Source: IMS (2006) #1 in Resuscitators (25% mkt share) #2 in Arterial blood gas kits (20% mkt share) #2 in Blood Pressure Cuffs (16% mkt share) Therapeutics Planned expansion to U.S. via SSA Sleep Ctrs Predominately Europe Diagnostics Expansion of sleep centers- both organically and through acquisition Sale of CPAP through ctrs Develop own Intellectual property and market through major companies Develop other companies products and manufacture for them (OEM) 7

8 Platform for Global Expansion Opportunities Single Patient Use Products Breas Sleep / Ventilation U.K. 6% Rest of Europe 5% Rest of the world 8% Rest of the world 10% Anesthesia Respiratory Critical Care U.S. 81% Europe 90% 8

9 Strengths in Anesthesia & Respiratory Business strengths Large recurring revenue stream from single-use airway management products Market leading products with strong brand recognition Longstanding relationships with hospitals, distributors and GPOs Single Patient Use products reduce nosocomial infections Strong R&D pipeline and stateof-the-art manufacturing Significant recurring revenue Rest of the world 8% Europe 11% U.S. 81% Single-use products contribute over 99% of revenue 9

10 Infection Control Initiatives 16 states now required to publicly report infection rates Legislation pending in virtually all remaining states 1 in 20 patients will develop a HAI¹ Hospital infections add over $30 B to the cost of healthcare in the U.S.¹ ¹Committee to Reduce Infection Deaths (RID), 10

11 Vital Signs Anesthesia-Safety and Innovation As of Q2 08 Vital Signs became the first anesthesia company to completely eliminate latex products in order to protect our employees, the hospital s employees, and patients Transitioned to our own JV in China lowered manufacturing costs (Q2 08) 11

12 New Products enflow Blood/Fluid Warmer $60 MM w.w. market Only device that warms and measures temperature near the patient Leverages anesthesiologist call point strength Single Patient Use Cartridge SteeLite Single Patient Use, Stainless Steel Laryngoscope Blade $100 MM w.w.market (with conversion to SPU) It is less expensive to use single patient blades than to sterilize a reusable Provides the best light transmission on market Redi-Tube Endotracheal tube with preloaded Stylet $45 MM market opportunity Combination provides speed for the clinician and safety for the patient Total New Market Opportunity $205 MM 12

13 Broselow Emergency System Color coded system that rapidly identifies and provides the correct medication and equipment sizes needed to treat pediatric emergencies Children are measured by length and are categorized into a color zone. This zone contains information about medicines, equipment, procedures, and emergency situations in an individual, color specific format. Accurate information is easy to access, and time delay is eliminated. 13

14 Broselow: Color Coding Kids Broselow-Luten Pediatric Error Prevention System In the six week study at Children s Hospital Boston and Massachusetts General Hospital for Children Researchers found 616 medication errors an error rate of 5.7 per cent Market size: $500 Million+ Manual system evolving to software based Based on preventing mathematical and written dosing errors Prescriptions written by color (universal language) Oral Dosing Syringe (consumer product) designed to prevent over/under-dosing of Tylenol 14

15 Favorable Industry Trends: Sleep Market Market factors 2 Market fundamentals 1 Large untapped OSA market million suffer from symptomatic or severe OSA in the U.S. 2.9 million sufferers are currently being treated Co-morbidities/awareness Increasing awareness by physicians and patients Co-morbidities include: diabetes, stroke, hypertension, congestive heart failure, depression and other 3 $ Billion CAGR: 15.4% Includes U.S. sleep diagnostic and treatment devices as well as sleep service provider markets 2 Frost & Sullivan 2005, Medtech Insight, IMS, company and analyst reports 3 American Academy of Sleep Medicine, 2005, Cost Effectiveness of Sleep Medicine 15

16 Sleep/Ventilation Overview: Dual Platform Business Overview Breas, based in Sweden, is a wellrecognized brand in Europe Breas manufactures sleep therapy equipment (isleep line), and ventilators for homecare (Vivo line) Afforded VSI entry into fastgrowing sleep and homecare ventilation markets Sales of ventilation products in US through specialty distributors Sales in U.S. through our managed sleep centers Sales by geography Rest of the world 10% Europe 90% 16

17 Today s Breas Products Vivo 30 Bi-level ventilator isleep 10 Conventional CPAP Vivo 40 Bi-level ventilator HA01 Humidifier isleep 20 Provides built-in humidifier isleep 20i Intelligent CPAP with built-in humidifier imask Ultra-soft Cushion Nasal mask isleep 22 Bi-level CPAP with humidifier The isleep line uses a sophisticated predictive algorithm in an aesthetically pleasing design and competes with the Resmed S8 and Respironics M series 17

18 Sleep Services of America Overview Ventures and partners with hospitals in the management of sleep labs SSA now operates 95 sleep diagnostic centers primarily on the east coast Vision: To progress from diagnosing sleep disorders to providing a more complete disease management solution by utilizing 8 hours/16+ channels of physiologic data Prestigious Sleep Lab affiliations Johns Hopkins University of Maryland Duke University Johns Hopkins owns 24% of SSA through a Joint Venture 18

19 FY 2008 Second Quarter (In Thousands except EPS figures) Q Q Net Change Net Revenues $58,934 $52, % Gross Profit 31,758 27, % Gross Margin 53.9% 52.0% 1.9% Income from Continuing Operations 9,886 8, % Net Income 9,970 8, % Diluted EPS $0.75 $ % 19

20 Q2 FY 2008 Net Revenue by Segment Net Revenues (In Thousands $) Q Q Net Change Anesthesia $19,816 $18, % Respiratory/Critical Care 12,304 11, % Sleep / Ventilation 16,634 12, % Interventional Cardiology/ Radiology 7,229 6, % 20

21 Balance Sheet Strengths and Cash Flow $117 million in cash plus $30 million in auction rate securities at 3/31/08. Approximately $11 / share Current Ratio is 10.3:1 Annualized dividends of $0.44 / share Generated $20.7 MM of cash from operations in first half of FY08 21

22 FY 2008 Guidance FY 2008 EPS Guidance of $2.82-$